Ghajar, A. and Khoaie-Ardakani, M.-R. and Shahmoradi, Z. and Alavi, A.-R. and Afarideh, M. and Shalbafan, M.-R. and Ghazizadeh-Hashemi, M. and Akhondzadeh, S. (2018) L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research, 262. pp. 94-101.
Full text not available from this repository.Abstract
Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted. Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study. The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks. The patients were assessed using the positive and negative syndrome scale (PANSS), extrapyramidal symptom rating scale (ESRS), and Hamilton depression rating scale (HDRS) during the study course. Sixty patients completed the trial. L-carnosine resulted in greater improvement of negative scores as well as total PANSS scores but not positive subscale scores compared to placebo. HDRS scores and its changes did not differ between the two groups. Both groups demonstrated a constant ESRS score during the trial course. Frequency of other side effects was not significantly different between the two groups. In a multiple regression analysis model (controlled for positive, general psychopathology, depressive and extrapyramidal symptoms, as well as other variables), the treatment group significantly predicted changes in primary negative symptoms. In conclusion, l-carnosine add-on therapy can safely and effectively reduce the primary negative symptoms of patients with schizophrenia. © 2018
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 0 |
| Uncontrolled Keywords: | carnosine; fluphenazine; haloperidol; lorazepam; olanzapine; placebo; risperidone, add on therapy; adult; Article; controlled study; depression; disease control; double blind procedure; drowsiness; drug dose increase; drug efficacy; drug safety; extrapyramidal symptom; extrapyramidal symptom rating scale; female; Hamilton Depression Rating Scale; headache; human; major clinical study; male; mental disease; nausea; negative syndrome; outcome assessment; parallel design; pilot study; Positive and Negative Syndrome Scale; priority journal; randomized controlled trial; rating scale; schizophrenia; side effect; sleep disorder; sweating; treatment duration; treatment response; xerostomia |
| Subjects: | WM Psychiatry |
| Depositing User: | eprints admin |
| Date Deposited: | 18 Dec 2018 11:00 |
| Last Modified: | 17 Aug 2019 05:57 |
| URI: | http://eprints.iums.ac.ir/id/eprint/6701 |
Actions (login required)
 |
View Item |
